Pixuvri®

 
Active substance Pixantrone
Holder S.A. Servier Benelux N.V.
Status closed
Indication monotherapy for the 3rd or 4th line treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B‐cell Lymphomas (NHL) (DLBCL and transformed indolent lymphoma)
Public documents Approbation
Information for the patient
Informed consent
Last update 09/10/2015
Last updated on 10/09/2024